CD33 and glioblastoma: Another strategy for dual targeting is to use different ligands that will separately target BBB and GBM.[57,88] A recent study led by Seok et al.[88] exploited liposomes with two targeting moieties attached to their surface: on one hand, angiopep-2 was used to achieve both BBB transcytosis and GBM targeting and, on the other hand, they used an anti-CD33 monoclonal antibody to reach stem cells.